GLP-1 Agonists Aid Diabetes, Long COVID Recovery
New research suggests that GLP-1 agonists, commonly used for diabetes and weight loss, may help treat pulmonary fibrosis in Long COVID patients. The study highlights the increased risk of severe COVID-19 complications for individuals with diabetes.
Why it matters
Repurposing existing diabetes medications could provide a critical treatment pathway for patients suffering from persistent, severe Long COVID symptoms.
Washington, D.C. - GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Findings from experiments on mice, published this week in the Journal of Virology , suggest that the drugs may offer benefits to another patient population: People with type 2 diabetes who suffer from pulmonary fibrosis months or years after infection with SARS-CoV-2, the virus that causes COVID-19.
The report is a straightforward summary of scientific findings published in a peer-reviewed journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in